1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 5 1.2 List of Figures 8 2 Introduction 9 2.1 Gastrointestinal Report Coverage 9 2.2 Non-Alcoholic Steatohepatitis (NASH) - Overview 9 2.3 Non Alcoholic Fatty Liver Disease (NAFLD) - Overview 9 3 Therapeutics Development 10 3.1 Non-Alcoholic Steatohepatitis (NASH) 10 3.2 Non Alcoholic Fatty Liver Disease (NAFLD) 29 4 Therapeutics Assessment 37 4.1 Non-Alcoholic Steatohepatitis (NASH) 37 4.2 Non Alcoholic Fatty Liver Disease (NAFLD) 48 5 Companies Involved in Therapeutics Development 58 5.1 Non-Alcoholic Steatohepatitis (NASH) 58 5.2 Non Alcoholic Fatty Liver Disease (NAFLD) 103 6 Dormant Projects 124 6.1 Non-Alcoholic Steatohepatitis (NASH) 124 6.2 Non Alcoholic Fatty Liver Disease (NAFLD) 127 7 Discontinued Products 129 7.1 Non-Alcoholic Steatohepatitis (NASH) 129 7.2 Non Alcoholic Fatty Liver Disease (NAFLD) 130 8 Product Development Milestones 131 8.1 Non-Alcoholic Steatohepatitis (NASH) 131 8.2 Non Alcoholic Fatty Liver Disease (NAFLD) 143 9 Appendix 158 9.1 Methodology 158 9.2 Coverage 158 9.3 Secondary Research 158 9.4 Primary Research 158 9.5 Expert Panel Validation 158 9.6 Contact Us 159 9.7 Disclaimer 159

1.1 List of Tables Table 1: Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH) 10 Table 2: Number of Products under Development by Companies, Non-Alcoholic Steatohepatitis (NASH) 12 Table 3: Number of Products under Development by Universities/Institutes, Non-Alcoholic Steatohepatitis (NASH) 16 Table 4: Products under Development by Companies, Non-Alcoholic Steatohepatitis (NASH) 17 Table 5: Products under Development by Universities/Institutes, Non-Alcoholic Steatohepatitis (NASH) 29 Table 6: Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) 30 Table 7: Number of Products under Development by Companies, Non Alcoholic Fatty Liver Disease (NAFLD). 31 Table 8: Number of Products under Development by Universities/Institutes, Non Alcoholic Fatty Liver Disease (NAFLD). 33 Table 9: Products under Development by Companies, Non Alcoholic Fatty Liver Disease (NAFLD). 33 Table 10: Products under Development by Universities/Institutes, Non Alcoholic Fatty Liver Disease (NAFLD). 36 Table 11: Number of Products by Stage and Target, Non-Alcoholic Steatohepatitis (NASH) 38 Table 12: Number of Products by Stage and Mechanism of Action, Non-Alcoholic Steatohepatitis (NASH) 42 Table 13: Number of Products by Stage and Route of Administration, Non-Alcoholic Steatohepatitis (NASH) 46 Table 14: Number of Products by Stage and Molecule Type, Non-Alcoholic Steatohepatitis (NASH) 48 Table 15: Number of Products by Stage and Target, Non Alcoholic Fatty Liver Disease (NAFLD) 50 Table 16: Number of Products by Stage and Mechanism of Action, Non Alcoholic Fatty Liver Disease (NAFLD) 53 Table 17: Number of Products by Stage and Route of Administration, Non Alcoholic Fatty Liver Disease (NAFLD) 56 Table 18: Number of Products by Stage and Molecule Type, Non Alcoholic Fatty Liver Disease (NAFLD) 57 Table 19: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AdAlta Ltd 58 Table 20: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Albireo Pharma Inc 58 Table 21: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Allergan Plc 59 Table 22: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Amunix Operating Inc 59 Table 23: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Aquinox Pharmaceuticals Inc 60 Table 24: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Arcturus Therapeutics Ltd 60 Table 25: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ardelyx Inc 61 Table 26: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Arisaph Pharmaceuticals Inc 61 Table 27: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Assembly Biosciences Inc 61 Table 28: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AstraZeneca Plc 62 Table 29: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by BASF SE 63 Table 30: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Betagenon AB 63 Table 31: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Bird Rock Bio Inc 63 Table 32: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by BLR Bio LLC 64 Table 33: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Boehringer Ingelheim GmbH 64 Table 34: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Bristol-Myers Squibb Co 65 Table 35: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cadila Healthcare Ltd 65 Table 36: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Can-Fite BioPharma Ltd 66 Table 37: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cardax Inc 66 Table 38: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Carmot Therapeutics Inc 67 Table 39: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Catabasis Pharmaceuticals Inc 67 Table 40: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cerenis Therapeutics Holding SA 68 Table 41: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ChemoCentryx Inc 68 Table 42: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CohBar Inc 69 Table 43: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Connexios Life Sciences Pvt Ltd 69 Table 44: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ConSynance Therapeutics Inc 69 Table 45: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CymaBay Therapeutics Inc 70 Table 46: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Daiichi Sankyo Co Ltd 70 Table 47: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Debiopharm International SA 71 Table 48: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dicerna Pharmaceuticals Inc 71 Table 49: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dimerix Bioscience Pty Ltd 72 Table 50: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dong-A Socio Holdings Co Ltd 72 Table 51: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by DURECT Corp 73 Table 52: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Eli Lilly and Co 73 Table 53: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Enanta Pharmaceuticals Inc 74 Table 54: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Enyo Pharma SA 74 Table 55: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Exicure Inc 75 Table 56: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Forma Therapeutics Inc 75 Table 57: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galectin Therapeutics Inc 75 Table 58: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galecto Biotech AB 76 Table 59: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galmed Pharmaceuticals Ltd 76 Table 60: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Gemphire Therapeutics Inc 77 Table 61: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Genfit SA 77 Table 62: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GenKyoTex SA 78 Table 63: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Gilead Sciences Inc 78 Table 64: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GlaxoSmithKline Plc 79 Table 65: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GRI Bio Inc 79 Table 66: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd 79 Table 67: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Hanmi Pharmaceuticals Co Ltd 80 Table 68: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by HemoShear Therapeutics, LLC 80 Table 69: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by iCo Therapeutics Inc. 81 Table 70: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Immuron Ltd 81 Table 71: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Intercept Pharmaceuticals Inc 82 Table 72: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Inventiva 82 Table 73: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ionis Pharmaceuticals Inc 83 Table 74: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Kissei Pharmaceutical Co Ltd 83 Table 75: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Kyorin Pharmaceutical Co Ltd 84 Table 76: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Madrigal Pharmaceuticals Inc. 84 Table 77: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Matinas BioPharma Holdings Inc 84 Table 78: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by MedImmune LLC 85 Table 79: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Merck & Co Inc 85 Table 80: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Metacrine Inc 86 Table 81: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Mitsubishi Tanabe Pharma Corp 86 Table 82: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Naia Ltd 87 Table 83: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NeuroVive Pharmaceutical AB 87 Table 84: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NGM Biopharmaceuticals Inc 88 Table 85: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Nippon Chemiphar Co Ltd 88 Table 86: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Novartis AG 89 Table 87: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NovaTarg Therapeutics Inc 89 Table 88: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Novo Nordisk AS 90 Table 89: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Nuevolution AB 90 Table 90: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ocera Therapeutics Inc 90 Table 91: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Oramed Pharmaceuticals Inc 91 Table 92: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Pfizer Inc 92 1.2 List of Figures Figure 1: Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH) 10 Figure 2: Number of Products under Development by Companies, Non-Alcoholic Steatohepatitis (NASH) 11 Figure 3: Number of Products under Development by Universities/Institutes, Non-Alcoholic Steatohepatitis (NASH) 16 Figure 4: Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) 29 Figure 5: Number of Products under Development by Companies, Non Alcoholic Fatty Liver Disease (NAFLD). 30 Figure 6: Number of Products by Top 10 Targets, Non-Alcoholic Steatohepatitis (NASH) 37 Figure 7: Number of Products by Stage and Top 10 Targets, Non-Alcoholic Steatohepatitis (NASH) 37 Figure 8: Number of Products by Top 10 Mechanism of Actions, Non-Alcoholic Steatohepatitis (NASH) 41 Figure 9: Number of Products by Stage and Top 10 Mechanism of Actions, Non-Alcoholic Steatohepatitis (NASH) 41 Figure 10: Number of Products by Routes of Administration, Non-Alcoholic Steatohepatitis (NASH) 45 Figure 11: Number of Products by Stage and Routes of Administration, Non-Alcoholic Steatohepatitis (NASH) 46 Figure 12: Number of Products by Top 10 Molecule Types, Non-Alcoholic Steatohepatitis (NASH) 47 Figure 13: Number of Products by Stage and Top 10 Molecule Types, Non-Alcoholic Steatohepatitis (NASH) 47 Figure 14: Number of Products by Top 10 Targets, Non Alcoholic Fatty Liver Disease (NAFLD) 48 Figure 15: Number of Products by Stage and Top 10 Targets, Non Alcoholic Fatty Liver Disease (NAFLD) 49 Figure 16: Number of Products by Top 10 Mechanism of Actions, Non Alcoholic Fatty Liver Disease (NAFLD) 51 Figure 17: Number of Products by Stage and Top 10 Mechanism of Actions, Non Alcoholic Fatty Liver Disease (NAFLD) 52 Figure 18: Number of Products by Routes of Administration, Non Alcoholic Fatty Liver Disease (NAFLD) 55 Figure 19: Number of Products by Stage and Routes of Administration, Non Alcoholic Fatty Liver Disease (NAFLD) 55 Figure 20: Number of Products by Top 10 Molecule Types, Non Alcoholic Fatty Liver Disease (NAFLD) 56 Figure 21: Number of Products by Stage and Top 10 Molecule Types, Non Alcoholic Fatty Liver Disease (NAFLD) 57

AdAlta Ltd Akcea Therapeutics Inc Albireo Pharma Inc Allergan Plc Amunix Operating Inc Aquinox Pharmaceuticals Inc Arcturus Therapeutics Ltd Ardelyx Inc Arisaph Pharmaceuticals Inc Assembly Biosciences Inc AstraZeneca Plc BASF SE Betagenon AB Bird Rock Bio Inc BLR Bio LLC Boehringer Ingelheim GmbH Bristol-Myers Squibb Co Cadila Healthcare Ltd Can-Fite BioPharma Ltd Cardax Inc Carmot Therapeutics Inc Catabasis Pharmaceuticals Inc Cerenis Therapeutics Holding SA ChemoCentryx Inc CJ HealthCare Corp CohBar Inc Connexios Life Sciences Pvt Ltd ConSynance Therapeutics Inc Corcept Therapeutics Inc CymaBay Therapeutics Inc Daewoong Pharmaceutical Co Ltd Daiichi Sankyo Co Ltd Debiopharm International SA Dicerna Pharmaceuticals Inc Dimerix Bioscience Pty Ltd Dong-A Socio Holdings Co Ltd Dr. Falk Pharma GmbH DURECT Corp Eli Lilly and Co Enanta Pharmaceuticals Inc Enyo Pharma SA Eternygen GmbH Evgen Pharma Plc Exicure Inc Forma Therapeutics Inc Galectin Therapeutics Inc Galecto Biotech AB Galmed Pharmaceuticals Ltd Gemphire Therapeutics Inc Genfit SA GenKyoTex SA Gilead Sciences Inc GlaxoSmithKline Plc GRI Bio Inc Guangdong Zhongsheng Pharmaceutical Co Ltd Hanmi Pharmaceuticals Co Ltd HemoShear Therapeutics, LLC Huons Global Co Ltd iCo Therapeutics Inc. Immuron Ltd Intercept Pharmaceuticals Inc Inventiva Ionis Pharmaceuticals Inc Kissei Pharmaceutical Co Ltd Kowa Co Ltd Kyorin Pharmaceutical Co Ltd Madrigal Pharmaceuticals Inc. Matinas BioPharma Holdings Inc MedImmune LLC Merck & Co Inc Metacrine Inc Mitsubishi Tanabe Pharma Corp Miyarisan Pharmaceutical Company Ltd Naia Ltd NeuroVive Pharmaceutical AB NGM Biopharmaceuticals Inc Nippon Chemiphar Co Ltd Novartis AG NovaTarg Therapeutics Inc Novo Nordisk AS Nuevolution AB Ocera Therapeutics Inc Oramed Pharmaceuticals Inc Pfizer Inc Pharmaxis Ltd Phenex Pharmaceuticals AG Promethera Biosciences SA ProMetic Life Sciences Inc Protalix BioTherapeutics Inc Redx Pharma Plc Regulus Therapeutics Inc reMYND NV Renova Therapeutics Inc Ritter Pharmaceuticals Inc Saje Pharma LLC Sancilio & Company Inc Sanofi Second Genome Inc Seres Therapeutics Inc Shenzhen HighTide Biopharmaceutical Ltd Shire Plc Sprint Bioscience AB Synlogic Inc TaiwanJ Pharmaceuticals Co Ltd TCM Biotech International Corp Theratechnologies Inc Tiziana Life Sciences Plc TRACON Pharmaceuticals Inc Translate Bio Inc Vascular Biogenics Ltd Verlyx Pharma Inc Viking Therapeutics Inc Zebra Discovery Ltd